Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02335476

Enrollment

100

Registered

2015-01-09

Start date

2015-03-31

Completion date

2017-04-30

Last updated

2016-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Keywords

optical coherence tomography

Brief summary

The investigators will use optical coherence tomography to detect the ex-vivo tissue image of surgical removed melanoma or other benign pigmented lesions of skin.

Detailed description

The investigators will use an advanced high resolution 3D optical coherence tomography (OCT) technology to observe skin tissue images in ex vivo culture. Parts of melanoma or benign pigmented lesions specimens derived from biopsy or surgical excision specimen will be observed by 3D optical tomography. A tiny tissue fragment of melanoma or benign pigmented lesions will be taken from surgical specimen without interference normal pathological evaluation. The location of melanocytic cells in melanoma or benign tissue fragments will be mapped by the 3D optical coherence tomography (OCT). The 3D optic tomography system utilize a Ce:YAG optical fiber as light source and also combined with confocal microscopy. Taken together, these features made the 3D optic tomography system have very high resolution and suitable for single cell imaging. This study will not interfere with the normal medical practice and had no impact on patient's safety and health. All of the materials will be destroyed once the experiments are done. The enrollment criteria will be dermatological patients who need to surgical intervention.

Interventions

None listed

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients aged older than 20 years old * Patients who had melanoma, melanoma in situ, and/or other benign pigmented lesions, * Patients who had non-melanoma skin cancers (basal cell carcinoma, or squamous cell carcinoma). * Patients who had precancerous skin lesions (Bowen's disease, actinicc keratosis)

Exclusion criteria

• Pregnant women.

Design outcomes

Primary

Measure	Time frame	Description
Ex vivo Tissue image.	1 day	Partial fragments of tissue specimens from melanoma, melanoma in situ, or other benign pigmented lesions will be used for imaging purpose by a optical coherence tomography.

Countries

Taiwan

Contacts

Primary ContactJENGWEI TJIU

jengweitjiu@gmail.com886-2-23123456

Outcome results